Table 4.
Summary of best responses observed with ipilimumab plus nivolumab in metastatic UM
| Characteristic | N (%) (95% CI) |
| CR | 1 (1) |
| PR | 9 (10) |
| SD | 21 (24) |
| PD | 55 (62) |
| Not available | 3 (3) |
| ORR | 10/86 (11.6) (5.7 to 20.3) |
| DCR | 31/86 (36) (26.0 to 47.1) |
| Median duration of response | 6.0 (3.0 to 10.3) months |
| OS, median, 95% CI | 15 (10.9 to 21.6) months |
| PFS, median, 95% CI | 2.7 (2.6 to 3.3) months |
CR, complete response; DCR, disease control rate; ORR, overall response rate; OS, overall survival; PD, progression of disease; PFS, progression free survival; PR, partial response; SD, stable disease; UM, uveal melanoma.